Aptahem reports additional positive biological effect in a Corona virus-induced acute lung injury model treated with Apta-1

Aptahem can today announce that in addition to previously reported positive preliminary data, the Toronto team has, from further studies, found essential positive effects in a Corona virus challenge induced Acute Lung Injury model with Apta-1 treatment. Studies show...

Read More

Aptahem receives patent protection in Japan for patent family 2

Aptahem AB (publ) announces today that the company has received patent protection in Japan for patent family 2 from the Japanese Patent Office (JPO). With JPO’s approval of patent application 2020-519806, the protection of the company’s drug candidate Apta-1...

Read More

BioStock article: Aptahem recruits to key positions before clinical studies

BioStock published an article on 4 February 2022 about Aptahem, which can be read in full below. Aptahem has recently recruited to fill three key positions ahead of the phase I studies planned with sepsis candidate Apta-1. Karin Aschan...

Read More